alexa New Ways Of Vision: Protein Structures In Translational Medicine And Business Development - My Experience
ISSN: 2169-0022

Journal of Material Sciences & Engineering
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

9th World Congress on Materials Science and Engineering
June 12-14, 2017 Rome, Italy

Robert Huber
Max Planck Institute of Biochemistry, Germany
Technical University of Munich, Germany
University of Duisburg-Essen, Germany
Keynote: J Material Sci Eng
DOI: 10.4172/2169-0022-C1-066
Abstract
As a student in the early nineteen sixties, I had the privilege to attend winter seminars organized by my mentor, W Hoppe, and by M Perutz, which took place in a small guesthouse in the Bavarian, Austrian Alps. The entire community of a handful of protein crystallographers assembled in a room which served as living and dining room and as auditorium for the lectures. Today structural biologists organize large congresses with thousands of attendants and there exist many hundreds of laboratories specialized in this field. It appears to dominate biology and biochemistry very visibly if we count covers in scientific journals displaying macromolecular structures. Structural biology was successful, because it was recognized that understanding biological phenomena at the molecular and atomic level requires seeing those molecules. Structural biology revealed the structure of genes and their basic mechanism of regulation, the mechanism of enzymes’ function, the structural basis of immune diversity, the mechanisms of energy production in cells by photosynthesis and its conversion into energy- rich chemical compounds and organic material, the mechanism that makes muscle work, the architecture of viruses and multi-enzyme complexes, and many more. New methods have an essential impact on the development of structural biology. Methods seem to become available in cadence with the growing complexity of the problems and newly discovered methods bring biological problems within reach for researchers, a co-evolutionary process of the development of methods and answerable problems, not only in the field of X-ray diffraction, but also in optical microscopy, nuclear magnetic resonance, and electron microscopy. An important additional incentive for structural biology came from its potential application for drug design and development using knowledge of drug receptor structures at the atomic level combined with theoretical approaches of ligand binding. The commercial interest in application spurred this direction of research enormously. My lecture will focus on protein crystallography and start out with the major factors contributing to its development. Few examples shall illustrate how structure information contributes to our understanding of the physical and chemical basis of biological phenomena and may lead to medical application. I then will let you share my experience with the foundation and development of two biotech companies with different business models, but both based on basic academic research in structural biology: Proteros (www.Proteros.com) offers enabling technology services for pharma- and crop science companies imbedding all steps of the workflow molecular and structural biology can provide and commands and uses its platform for the generation of leads from identified targets to in vivo Proof-of-Concept (PoC). Suppremol (www.Suppremol.com) specializes in the development of novel immune-regulatory therapeutics for the treatment of autoimmune diseases on the basis of a recombinant, soluble, nonglycosylated version of the human Fcg receptor IIB and of receptor binding antibodies. Suppremol was recently acquired by Baxter International Inc. (NYSE:BAX) offering an ideal setting for its therapeutic projects.
Biography

Robert Huber is Director at the Max Planck Institute for Biochemistry, where his team developed methods for the crystallography of proteins. In 1988, he received the Nobel Prize for Chemistry jointly with Johann Deisenhofer and Hartmut Michel. Three were recognized for their work in first crystallizing an intra-membrane protein important in photosynthesis in purple bacteria, and subsequently applying X-ray crystallography to elucidate the protein's structure. The information provided the first insight into the structural bodies that performed the integral function of photosynthesis. This insight could be translated to understand the more complex analogue of photosynthesis in cyanobacteria which is essentially the same as that in chloroplasts of higher plants. In 2006, he took up a post at the Cardiff University to spearhead the development of structural biology at the university on a part-time basis. Since 2005, he has been doing research at the Center for Medical Biotechnology of the University of Duisburg-Essen. He was one of the original editors of the “Encyclopedia of Analytical Chemistry”.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords